Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cooperative Study Group A for Hematology
• Treatments: Fludarabine; Fludarabine phosphate; Melphalan; Vidarabine

Criteria

Inclusion Criteria:

• Patients must be 15 years of age or older and 65 years of age or younger

• Patients with CLL, lymphoma, or multiple myeloma will be included in this study

• No prior anti-cancer treatment should be done within 30 days.

• Informed consent should be given.

• Patients should have an HLA-identical or single HLA-locus mismatched donor.

• Karnofsky performance scale should be 50 or over (see Appendix I).

Exclusion Criteria:

• Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the stem cell transplant treatment unlike, and making informed consent impossible.

• Patients with high serum creatinine level will be excluded.

• Patients should have uncontrolled infection.

• No major anticipated illness or organ failure incompatible with survival from stem cell transplant.

• Serum bilirubin less than or equal to 4.0 mg/dL.